Trends in antihypertensive medicine utilization in the Republic of Srpska, Bosnia and Herzegovina : an eleven-year follow-up

Kalinić, Dragan and Škrbić, Ranko and Vulić, Duško and Stojaković, Nataša and Stoisavljević-Šatara, Svjetlana and Stojiljković, Miloš and Markovic-Pekovic, Vanda and Jelić, Ana and Pilipović-Broćeta, Nataša and Wong, Nathan and Godman, Brian (2022) Trends in antihypertensive medicine utilization in the Republic of Srpska, Bosnia and Herzegovina : an eleven-year follow-up. Frontiers in Pharmacology, 13. 889047. ISSN 1663-9812 (

[thumbnail of Kalinic-etal-FiP-2022-Trends-in-antihypertensive-medicine-utilization-in-the-Republic-of-Srpska-Bosnia-and-Herzegovina]
Text. Filename: Kalinic_etal_FiP_2022_Trends_in_antihypertensive_medicine_utilization_in_the_Republic_of_Srpska_Bosnia_and_Herzegovina.pdf
Final Published Version
License: Creative Commons Attribution 4.0 logo

Download (1MB)| Preview


Background: In last 2 decades, there have been substantial changes in the utilization patterns of antihypertensive medicines following new clinical trials and the introduction of new treatment guidelines. The aim of this study was to analyze utilization and prescribing patterns regarding antihypertensive medicines in the Republic of Srpska, Bosnia and Herzegovina during an 11-years follow-up according to national and European treatment guidelines. Methods: In this retrospective, observational study, medicine utilization data were analyzed between 2009–2019 period using the ATC/DDD methodology and expressed as the number of DDD/1,000 inhabitants/day (DID/TID). The medicine utilization 90% (DU90%) method was used for determine the quality of prescribing. Results: During the observed period, the use of antihypertensive medicines increased more than 3-times (125.97 DDD/TID in 2009 vs 414.95 DDD/TID in 2019), corresponding to a rise in the prevalence of hypertensive patients from 91.7/1,000 to 186.3/1,000 in the same period. This was mainly driven by increased use of angiotensin converting enzyme inhibitors with 241.69%, beta blockers with 146.87%, calcium channel blockers with 251.55%, and diuretics with 178.95%. Angiotensin receptor blockers were the fastest growing group of antihypertensive medicines in this period and their utilization increased nearly 40 times. Conclusions: The overall antihypertensive medicines utilization was largely influenced by national and ESH/ESC guidelines and strongly corresponded to the positive medicine list of the national health insurance fund. Antihypertensive medicines utilization is comparable with medicine utilization trends in other countries.